Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 Inhibitors
The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
Recently, the U.S. Food and Drug Administration (FDA) issued a Drug Safety Communication that warns of an increased risk of diabetic ketoacidosis (DKA) with uncharacteristically mild to moderate glucose elevations (euglycemic DKA [euDKA]) associated with the use of all the approved sodium-glucose cotransporter 2 (SGLT2) inhibitors (1).This Communication was based on 20 clinical cases requiring hospitalization captured between March 2013 and June 2014 in the FDA Adverse Event Reporting System database.The scarce clinical data provided suggested that most of the DKA cases were reported in patients with type 2 diabetes (T2D), for whom this class of agents is indicated; most likely, however, they were insulintreated patients, some with type 1 diabetes (T1D).The FDA also identified potential triggering factors such as intercurrent illness, reduced food and fluid intake, reduced insulin doses, and history of alcohol intake.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Patients with either T1DM or T2DM taking insulin are at particular risk, with the greatest risk for ketoacidosis in T1DM.”
From SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation (2021) · cites this paper as [90]
In the citing paper
“Euglycemic ketoacidosis with minimal to no elevation in blood glucose levels may occur in patients taking SGLT2 inhibitors due to increased fatty acid oxidation and glucagon release along with decreased insulin secretion (89,90).”
From SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation (2021) · cites this paper as [90]
Citations
Cites
Nathan, D. M., & for the DCCT/EDIC Research Group (2014) · Diabetes Care · doi:10.2337/dc13-2112 · Cited by 1,832
Miller, K. M., Foster, N. C., Beck, R. W., Bergenstal, R. M., DuBose, S. N., DiMeglio, L. A., Maahs, D. M., & Tamborlane, W. V. (2015) · Diabetes Care · doi:10.2337/dc15-0078 · Cited by 1,254
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
Ferrannini, E., Muscelli, E., Frascerra, S., Baldi, S., Mari, A., Heise, T., Broedl, U. C., & Woerle, H.-J. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72227 · Cited by 1,134 · cited 4×
“Thus, in SGLT2-treated T2D patients (17), the lower insulin-to-glucagon ratio stimulated lipolysis (circulating FFAs were ;40% higher during the meal) and enhanced lipid oxidation (by 20% on av-”
BackgroundInfluentialSelf-citationPeters, A. L., Buschur, E. O., Buse, J. B., Cohan, P., Diner, J. C., & Hirsch, I. B. (2015) · Diabetes Care · doi:10.2337/dc15-0843 · Cited by 849
Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production
Merovci, A., Solis-Herrera, C., Daniele, G., Eldor, R., Fiorentino, T. V., Tripathy, D., Xiong, J., Perez, Z., Norton, L., Abdul-Ghani, M. A., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci70704 · Cited by 795 · cited 1×
“of the euglycemic insulin clamp, as a result of attenuated glucotoxicity (21).”
BackgroundInternational Textbook of Diabetes Mellitus
(2004) · Wiley eBooks · doi:10.1002/0470862092 · Cited by 725
Bonner, C., Kerr-Conte, J., Gmyr, V., Queniat, G., Moerman, E., Thévenet, J., Beaucamps, C., Delalleau, N., Popescu, I., Malaisse, W. J., et al. (2015) · Nature Medicine · doi:10.1038/nm.3828 · Cited by 670
Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program
Erondu, N., Desai, M., Ways, K., & Meininger, G. (2015) · Diabetes Care · doi:10.2337/dc15-1251 · Cited by 324
Euglycaemic Diabetic Ketoacidosis
Munro, J. F., Campbell, I. W., McCuish, A. C., & Duncan, L. J. P. (1973) · BMJ · doi:10.1136/bmj.2.5866.578 · Cited by 323
Insulin within islets is a physiologic glucagon release inhibitor
Maruyama, H., Hisatomi, A., Orci, L., Grodsky, G. M., & Unger, R. H. (1984) · Journal of Clinical Investigation · doi:10.1172/jci111658 · Cited by 303 · cited 1×
“In contrast, plasma glucagon concentrations increased significantly, partly because of a diminished paracrine inhibition by insulin (18) and possibly also because of decreased SGLT2-mediated glucose transport intoa-cells (19).”
Background
Cited by
Items 501–600 of 685
de Windt, F., Mancebo-Sevilla, J. J., & Fernández-Truchaud, A. (2020) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2020.09.016 · Cited by 1
Proposed mechanisms of systemic cardiovascular action of gliflosins
Zverev, Y. F., & Rykunova, A. Y. (2021) · Reviews on Clinical Pharmacology and Drug Therapy · doi:10.17816/rcf1915-22 · Cited by 1
Recent Advances in Sodium Glucose Cotransporter-2 Inhibitors
Cho, D. H. (2021) · Journal of Korean Diabetes · doi:10.4093/jkd.2021.22.2.113 · Cited by 1
Hafer, C. (2021) · Intensivmedizin up2date · doi:10.1055/a-1202-9010 · Cited by 1
“Das niedrige Insulin/Glukagon-Verhältnis führt zu einer erhöhten Lipolyse und der Freisetzung freier Fettsäuren, die durch β-Oxidation in Ketonkörper umgewandelt werden [48,49].”
BackgroundAn insight to the diabetic ketoacidosis and lactic acidosis among the SARS-COV2 infected individuals
Al-Sa'idy, H. A. H., Al‐Snafi, A. E., & Alyousif, B. (2022) · Magna Scientia Advanced Biology and Pharmacy · doi:10.30574/msabp.2022.6.1.0071 · Cited by 1
Bell-McClure, E., Sabol, V. K., & McMillan, K. (2022) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2022.11.011 · Cited by 1
Important Dietary Considerations for Sodium-Glucose Cotransporter 2 Inhibitors
Anthamatten, A. (2023) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2022.104527 · Cited by 2
Rotman‐Pikielny, P., Lurie, T. H., Rabia, R., Twito, O., Rosenblum, R. C., & Barzilay-Yoseph, L. (2023) · Endocrine Practice · doi:10.1016/j.eprac.2023.06.010 · Cited by 1
Krentz, A. J. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-91707-0.00001-2 · Cited by 1
Petersen, M. C., Jones, K. E., Markov, A. M., Salam, M., Krutilova, P., McKee, A. M., Bohnert, K. L., Adamson, S. E., & McGill, J. B. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16324 · Cited by 1
“32 Although dapagliflozin reduced the total daily insulin dose by approximately 10% in our study participants, this reduction would not explain the greater ketone concentrations observed upon insulin withdrawal.”
Alheijani, B., Alswaidan, A. T., Swaidan, O. T. A., & Alheijani, A. B. (2025) · Cureus · doi:10.7759/cureus.90403 · Cited by 1
“It usually occurs when an absolute insulin deficiency leads to decreased glucose utilization, enhanced lipolysis, and increased delivery of free fatty acids (FFAs) to the liver, where they are converted into ketone bodies [1].”
InfluentialDuration of DKA and Insulin Use in People with and Without SGLT2 Inhibitor Medications
Park, Y., Lee, A. K., Barmanray, R., Gao, F. M., Fourlanos, S., & Gilfillan, C. P. (2025) · Medicines · doi:10.3390/medicines12030021 · Cited by 1
“Traditionally, DKA presents with hyperglycemia and ketoacidosis; however, with SGLT2i use, patients may present with euglycemic DKA [9].”
Huang, Y., Yu, X., & Li, C. (2025) · CNS Drugs · doi:10.1007/s40263-025-01230-3 · Cited by 1
“Owing to the promotion of urinary glucose excretion by SGLT2i, long-term use results in carbohydrate losses ranging from 17% to 44% [140].”
Aotani, R., Ohkuma, T., Oshiro, A., Okamura, K., & Ago, T. (2025) · Case Reports in Endocrinology · doi:10.1155/crie/8872854 · Cited by 1
“DKA can occur in patients under treatment with SGLT2 inhibitors, even in the presence of uncharacteristically mild to moderate glucose elevations [6], as observed in the present case (blood glucose level: 17.2 mmol/L).”
InfluentialTakanami, H., Kubo, K., Sakamoto, S., Masuzawa, M., & Kamibayashi, T. (2025) · Cureus · doi:10.7759/cureus.100409 · Cited by 1
“Patients who receive SGLT2i are at risk for hyperketonemia if surgical stress increases insulin resistance or decreases secretion [6].”
Euglycemic Ketoacidosis Induced by Dapagliflozin in a Non‐Diabetic Patient With Cardiac Amyloidosis
Hamoud, S. A. S., & Harding, E. (2026) · Clinical Case Reports · doi:10.1002/ccr3.71818 · Cited by 1
Montasser, M. E., Bargal, S. A., Streeten, E. A., Whitlatch, H. B., Yazdi, Z. S., Sirody, J., Kiplagat, R., Beshara, M., O’Connell, J. R., Taylor, S. I., et al. (2026) · Clinical and Translational Science · doi:10.1111/cts.70594 · Cited by 1
To Hold or Not to Hold, That Is the Question: Sick Day Medication Guidance as Routine Care
Thavarajah, S. (2026) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2026.01.019 · Cited by 1
Canagliflozin induced diabetic ketoacidosis
Felechosa, M. D., & Suárez-Gutiérrez, L. (2016) · Endocrinología y Nutrición (English Edition) · doi:10.1016/j.endoen.2016.09.013 · Cited by 1
Basile, J. (2016) · Hospital Practice · doi:10.1080/21548331.2016.1141656 · Cited by 2
“[105] Diabetic ketoacidosis has occurred in euglycemic patients taking SGLT2 inhibitors.[106] Treatment-”
BackgroundSodium-glucose cotransporter 2 inhibitors and cardiovascular outcomes
Steinberg, H. O. (2016) · Postgraduate Medicine · doi:10.1080/00325481.2016.1168687 · Cited by 2
“1% for blinded DKA events in ≈7000 patients from the EMPA-REG OUTCOME trial).[53,54]”
BackgroundSGLT2-remmers en diabetische ketoacidoses
IJzerman, R. G. (2015) · Nederlands Tijdschrift voor Diabetologie · doi:10.1007/s12467-016-0003-y · Cited by 1
SGLT2 Inhibitors for Treating Diabetes
McKay, G. A., & Livingstone, R. (2016) · Springer eBooks · doi:10.1007/978-3-319-43296-0_2 · Cited by 2
Euglycemic diabetic ketoacidosis with SGLT2 inhibitors in lean type 2 diabetes
Kim, M.-K. (2016) · Integrative Obesity and Diabetes · doi:10.15761/iod.1000157 · Cited by 1
“Recently, there are case reports of diabetic ketoacidosis in patients with type 1 diabetes or T2DM treated with SGLT2 inhibitors [7-9].”
BackgroundRaut, M., & Maheshwari, A. (2017) · Indian Journal of Anaesthesia · doi:10.4103/ija.ija_359_17 · Cited by 1
“This is suggestive of acceptably very low occurrence.[1]”
BackgroundЛебедев, Д. А., & Babenko, A. Y. (2018) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2018-16-100-108 · Cited by 1
Jiménez-Montero, J. G., Mora-Aguilar, C. J., & Chen-Ku, C. H. (2018) · AACE Clinical Case Reports · doi:10.4158/accr-2018-0113 · Cited by 2
Obregón, F. M., Montoro, A. E., Martín, J. M., & Jiménez, D. L. (2019) · Atención Primaria · doi:10.1016/j.aprim.2019.04.007 · Cited by 2
Inibitori di SGLT-2 e chetoacidosi euglicemica: conoscere per prevenire
Falcetta, P., Indovina, F. S., Coppelli, A., Daniele, G., & Prato, S. D. (2019) · L Endocrinologo · doi:10.1007/s40619-019-00646-6 · Cited by 1
A case of metabolic encephalopathy associated with euglycemic diabetic ketoacidosis
Na, S., Lee, M.-A., & Song, I. (2019) · Neurological Sciences · doi:10.1007/s10072-019-04161-2 · Cited by 1
SGLT2-Inhibitoren bei diabetischer Nephropathie: Mechanismen und klinische Wirkung
Dumann, E., Haller, H. G., & Menne, J. (2020) · Der Nephrologe · doi:10.1007/s11560-020-00410-0 · Cited by 1
Factors that predict glycaemic response to sodium‐glucose linked transporter (SGLT) inhibitors
Harding, A. L., Bediaga, N. G., Galligan, A., Colman, P. G., Fourlanos, S., & Wentworth, J. M. (2021) · Internal Medicine Journal · doi:10.1111/imj.14805 · Cited by 1
Motor-evacuation function of the stomach in patients with diabetes mellitus
Турғунпулатовна, Д. Л., & Muminova, S. (2019) · Экспериментальная и клиническая гастроэнтерология · doi:10.31146/1682-8658-ecg-172-12-95-100 · Cited by 1
Uncovering Autoimmune Diabetes in a Patient With Euglycemic Diabetic Ketoacidosis
Schempf, J., Chow, L. S., & Harindhanavudhi, T. (2020) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2020.05.022 · Cited by 1
Kır, S., & Tiken, İ. (2020) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-020-00823-6 · Cited by 1
Optimizing Management of Type 2 Diabetes and Its Complications in Patients With Heart Failure
Schumacher, C., Dril, E. V., Shealy, K. M., & Goldman, J. D. (2020) · Clinical Diabetes · doi:10.2337/cd20-0008 · Cited by 1
Ranasinghe, U., & Acharya, S. (2021) · International Journal of Diabetes and Clinical Research · doi:10.23937/2377-3634/1410140 · Cited by 2
Kaur, A., Singh, P., Singh, G., Mohan, G., Chopra, G., & Singh, R. (2021) · International Journal of Advances in Medicine · doi:10.18203/2349-3933.ijam20212875 · Cited by 1
“Docherty et al described that in diabetic patients with HF, the reductions in the risk of worsening HF and cardiovascular death with dapagliflozin is found and it is recommended as first-line monotherapy.5 The food and drug administration (FDA) has approved three SGLT-2 inhibitors as monotherapy for patients with T2DM…”
InfluentialThe Impact of Carbohydrate Restriction and Nutritional Ketosis on Cardiovascular Health
Lowe, D. A., Corbit, K. C., & Weiss, E. J. (2021) · Contemporary cardiology · doi:10.1007/978-3-030-78177-4_5 · Cited by 1
Labordiagnostik bei Menschen mit Diabetes
Hörber, S., Heni, M., & Peter, A. (2021) · Der Diabetologe · doi:10.1007/s11428-021-00813-0 · Cited by 1
“vermehrt Ketoazidosen bei nur leicht erhöhten und auch normwertigen Glukosekonzentrationen beobachtet [15].”
BackgroundManagement of Acute Complications of Diabetes Mellitus
Bae, J. H., & Kim, S. G. (2021) · Stroke revisited · doi:10.1007/978-981-16-5123-6_19 · Cited by 2
Meredith, A. H., Starks, S., Etelamaki, C., Albertson, S., Triboletti, J. S., Pence, L. M., Walroth, T. A., McGrew, K., & Gonzalvo, J. D. (2021) · ADCES in Practice · doi:10.1177/2633559x211056918 · Cited by 1
Euglycemic Diabetic Ketoacidosis in a Diabetic Patient Treated with SGLT2 Inhibitor
Lavrynenko, O., Hector, S., Amando, G., Qazi, R., & Leopoldo, C. (2021) · Clinical Diabetes and Research · doi:10.36959/647/497 · Cited by 1
Soni, H. (2015) · MOJ Toxicology · doi:10.15406/mojt.2015.01.00021 · Cited by 2
Dapagliflozin Causing Euglycemic Diabetic Ketoacidosis
Kela, M. M. (2023) · Journal of Research & Innovation in Anesthesia · doi:10.5005/jp-journals-10049-2020 · Cited by 1
Ketonuria in an adult with Prader-Willi syndrome and diabetes mellitus: A case report
Xu, X., Wang, D., Pan, H., Li, J., Li, B., & He, Z. (2024) · Medicine · doi:10.1097/md.0000000000037096 · Cited by 1
“[16,17] However, during conditions of fasting, surgery, acute infection, or insulin deprivation, the occurrence of DKA is markedly augmented.”
BackgroundSGLT-2i associated diabetic ketoacidosis in the setting of cardiogenic shock
Guzner, A., Downs, I. A., Cruz, D., Kaneshiro, C., & Donangelo, I. (2024) · BMJ Case Reports · doi:10.1136/bcr-2023-258017 · Cited by 2
Zaghloul, N., Awaisu, A., Mahfouz, A., Ali, Z. O., Alyafei, S., & Elewa, H. F. (2024) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-024-01828-5 · Cited by 1
“However, SGLT2is have been associated with an increased risk of bone fractures [12], urinary tract infections (UTIs) [13], metabolic acidosis [14], and amputations [15].”
Ojaimi, R. E., Cheisson, G., Cosson, E., Ichaï, C., Jacqueminet, S., Catargi, B., Ouattara, A., Tauveron, I., Valensi, P. E., & Benhamou, D. (2024) · Anaesthesia Critical Care & Pain Medicine · doi:10.1016/j.accpm.2024.101468 · Cited by 1
Patel, K. S., & Carbone, A. M. (2020) · Annals of Pharmacotherapy · doi:10.1177/1060028020910246 · Cited by 1
Diabetische Ketoazidosen unter Canagliflozin
Jecht, M. (2015) · Der Diabetologe · doi:10.1007/s11428-015-0030-0
Vardarli, I., & Özcelik, C. (2016) · Der Kardiologe · doi:10.1007/s12181-016-0047-7
Can a Diabetic Medication offer Cardiovascular benefits?
Ukrainski, M. (2016) · Journal of Diabetes Research and Therapy · doi:10.16966/2380-5544.e102
“The risk of diabetic ketoacidosis, especially among Type 1 diabetics and insulin dependent Type 2 diabetics, has emerged as a serious complication [5,6].”
BackgroundBessere Aussichten für Patienten mit Typ-2-Diabetes
Ritzel, R. A. (2016) · MMW - Fortschritte der Medizin · doi:10.1007/s15006-016-7701-7
“Kürzlich wurde auch bei einzelnen Personen mit Typ-2-Diabetes unter SGLT2Inhibitoren ein erhöhtes Risiko für diabetische Ketoazidosen bei vergleichsweise gering erhöhten Glukosekonzentrationen be schrie ben [10].”
BackgroundCLEMENT, M. A., & Senior, P. A. (2016) · Europe PMC (PubMed Central)
Клініко-діагностичні аспекти діабетичного кетоацидозу
Nizhynska-Аstapenko, Z. P., & Vlasenkо, М. V. (2016) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.4.76.2016.77814
Cetoacidosis diabética asociada a tratamiento con canagliflozina
Felechosa, M. D., & Suárez-Gutiérrez, L. (2016) · Endocrinología y Nutrición · doi:10.1016/j.endonu.2016.05.008
SGLT2 inhibitor associated diabetic ketoacidosis
Mitsiou, E., Mandros, C., Kotsa, K., Koulis, F., Christofidis, C., Georgiadi, S., Testa, T., Anastasiou, A., Efthymiou, E., & Potolidis, E. (2017) · International Journal of Case Reports and Images · doi:10.5348/ijcri-201740-cr-10779
“Inhibition of SGLT2 causes a rapid increase in urinary volume excretion, which lasts more than 24 hours [8].”
BackgroundL’acidocétose diabétique euglycémique due à la canagliflozine
CLEMENT, M. A., & Senior, P. A. (2016) · Canadian Family Physician
Kueh, C. J., Connelly, P. J., Harte, R., Smith, C., & Boyle, J. G. (2017) · Practical Diabetes · doi:10.1002/pdi.2100
Новые перспективы применения ингибиторов натрий-глюкозного котранспортёра 2 при сахарном диабете
Байрашева, В. К., Pchelin, I. Y., Arefeva, A., Andoskin, P. A., Vasilkova, V., Лебедев, Д. А., & Чефу, С. Г. (2017) · Juvenis scientia
Closing anion gap without insulin in euglycaemic diabetic ketoacidosis
Poudel, R., & Kafle, N. (2017) · Journal of Diabetology · doi:10.4103/jod.jod_26_17
Hans, F. P., & Busch, H.-J. (2018) · Der Diabetologe · doi:10.1007/s11428-017-0298-3
“Sie kann außer in der Schwangerschaft auch unter antidiabetischer Medikation mit SGLT-2-Inhibitoren auftreten [8].”
MethodBianchi, C., Daniele, G., Dardano, A., & Prato, S. D. (2018) · Endocrinology · doi:10.1007/978-3-319-27317-4_19-1
Gestione terapeutica del diabete di tipo 2
Rigalleau, V., Cherifi, B. G., Blanco, L., Alexandre, L., & Mohammedi, K. (2018) · EMC - AKOS - Trattato di Medicina · doi:10.1016/s1634-7358(18)90444-4
Cetoacidosis diabética euglucémica
González-Castro, A., Lasa, M. O., & Alfonso, A. J. (2018) · Medicina Clínica · doi:10.1016/j.medcli.2018.05.029
Hans, F. P., & Busch, H.-J. (2018) · Notfall + Rettungsmedizin · doi:10.1007/s10049-018-0497-5
Ivers, N. M., Jiang, M., Alloo, J., Singer, A. G., Ngui, D., Casey, C. G., & Yu, C. H. Y. (2019) · Europe PMC (PubMed Central)
What Next After Metformin? Guidelines and Indian Context
Hb, C. (2017) · Current Research in Diabetes & Obesity Journal · doi:10.19080/crdoj.2017.05.555658
“This potential complication related to SGLT2 inhibition is predictable, detectable, and preventable so that the balance of benefits and risks favors the use of SGLT2 inhibitors in the T2DM population [58].”
BackgroundTwenty years of adverse drug reactions: a look back – part 2
Ferner, R. E., & Anton, C. (2018) · Adverse Drug Reaction Bulletin · doi:10.1097/fad.0000000000000034
Diabetic Pharmacotherapies in Kidney Disease
Chon, D. A., Oxman, R. T., MULLUR, R. S., & Weinreb, J. E. (2019) · Springer eBooks · doi:10.1007/978-3-319-97765-2_5
Sodium Glucose Cotransporter-2 (SGLT-2) Inhibitor Related Diabetic Ketoacidosis
Kula, A. C., Hoca, E., Ahbab, S., & Ataoğlu, H. E. (2019) · European Scientific Journal ESJ · doi:10.19044/esj.2019.v15n15p268
Sodium-Glucose Cotransporter 2 Inhibitors
DAILEY, G. E., Clarine, L., & Rodríguez-Martínez, R. (2019) · Springer eBooks · doi:10.1007/978-3-030-11815-0_34
Prise en charge thérapeutique du diabète de type 2
Rigalleau, V., Cherifi, B., Blanco, L., Alexandre, L., & Mohammedi, K. (2017) · Time to knit · doi:10.1016/s1634-6939(17)69798-9 · Cited by 2
Jiménez-Montero, J. G. (2019) · International Journal of Endocrinology and Metabolic Disorders · doi:10.16966/2380-548x.154 · Cited by 1
“This complication has been observed in the context of certain predisposing factors, which includes reduction in insulin provision, infections, surgery, alcohol intake and dietary derangements [11-16].”
BackgroundGreenberg, C. A. (2018) · YorkSpace (York University)
Euglycemic diabetic ketoacidosis: another masquerader!
Kumar, B., Thangavelu, S., & Prabhakar, R. (2019) · International Journal of Basic & Clinical Pharmacology · doi:10.18203/2319-2003.ijbcp20194283
Atypical Feature of Diabetic Ketoacidosis with Low or Normal Plasma Glucose: a Narrative Review
Niroomand, M., & Jalili, M. (2020) · DOAJ (DOAJ: Directory of Open Access Journals) · doi:10.22114/ajem.v0i0.274
Levit, S., Giveon, S. M., Musin, I. N., Barnea, R., Korek-Abadi, I., Levit, V. M., Ryder, D., & Ryder, C. H. (2019) · Pharmacy Formulas · doi:10.17816/phf18536
Problem solving in type 1 diabetes for primary care nurses
Morris, D. (2019) · Independent Nurse · doi:10.12968/indn.2019.9.4 · Cited by 3
TXNIP and the GAPDH-Siah1 Signalling Pathway in Diabetic Nephropathy
Zhong, H. (2019) · TSpace (University of Toronto)
Lethargy in a patient with diabetes: A diagnosis not to be missed.
Hussain, K., Hussain, S., & Hassan, M. (2020) · Australian Journal of General Practice · doi:10.31128/ajgp-06-19-4970
SGLT 2 inhibitor induced euglycemic ketoacidosis
Dhivahar, G., Balasubramanian, D. S., Dr Raghunath, D., & Misra, S. (2020) · Surgical Update International Journal of Surgery and Orthopedics · doi:10.17511/ijoso.2020.i01.12
“The treatment for SGLT2 inhibitor induced ketoacidosis is similar to diabetic ketoacidosis involving aggressive rehydration and insulin therapy even when the blood glucose level is not very high [9,10].”
BackgroundAtypische diabetische Ketoazidose bei Patienten mit Typ-2-Diabetes unter SGLT-2-Therapie
Kopf, S. (2020) · Diabetes aktuell · doi:10.1055/a-1095-4394
“Dabei entstehen Acetessigsäure und Beta-Hydroxybuttersäure (sogenannte Ketonkörper) – diese führen langfristig zur Übersäuerung (metabolische Azidose) des Körpers [11].”
BackgroundInfluentialKardiovaskuläre Effekte von SGLT-2-Inhibitoren
Mustroph, J., & Neef, S. (2020) · Diabetes aktuell · doi:10.1055/a-1152-2157
“im Kontext einer endokrinen Pankreas insuffizienz berichtet und insgesamt als vermeidbar eingeschätzt werden [20].”
BackgroundJha, S. K., Singh, N. K., & Mahajan, A. (2020) · doi:10.9734/ajrre/2020/v3i111
“After their introduction 101 cases of SGLT-2 inhibitor induced DKA were reported till may 2015 which led FDA to release a warning about this concern with SGLT-2 inhibitor use [8,9].”
BackgroundEndocrine Emergencies in the ICU
Whisenant, B. (2020) · Springer eBooks · doi:10.1007/978-3-030-28794-8_26
Glyphozines and treatment of cardiac disease
Ferrara, F., Granata, G., Pelliccia, C., Porta, R. L., & Vitiello, A. (2020) · Geriatric Care · doi:10.4081/gc.2020.9079
SGLT2 Inhibitors: A Noval Therapuetic Agent in the Treatment of Diabetic Kidney Disease
Thasneem, K. V. M., Sreejith, K., Athulnadh, B., Maniyan, N., Neena, C. C., & Faris, P. P. M. (2020) · Journal of Drug Delivery and Therapeutics · doi:10.22270/jddt.v10i6.4532
Underwood, L., Semchuk, W., & Albers, L. (2020) · Canadian Pharmacists Journal / Revue des Pharmaciens du Canada · doi:10.1177/1715163520976149
“To reduce the risk, all patients should have a sick day management plan, with instructions to hold SGLT2 inhibitors in cases of illness with vomiting or diarrhea, avoiding low-carbohydrate diets and avoiding excessive alcohol intake.(7,25,26) FD is comfortable with the information reviewed during a counselling session…”
BackgroundMason, T. (2020) · TSpace (University of Toronto)
Building therapy in type 2 diabetes – metformin and beyond
Morris, D. (2021) · Independent Nurse · doi:10.12968/indn.2021.3.14
Diabetic Ketoacidosis: Visiting an All Too Familiar Preventable Emergency
Reece, S. W., Beltrán, A. R., Nattama, S., & Adcock, K. (2021) · ADCES in Practice · doi:10.1177/2633559x211008153
Sodium-glucose co-transporter 2 inhibitors: game changers when handled with care?
Htet, Z. M., & Karim, M. (2021) · Journal of the Royal Society of Medicine · doi:10.1177/01410768211011109
“As a result of the reduced renal glucose excretion threshold and increased glycosuria, the majority of reported cases of ketoacidosis presented with euglycaemia or only a modest rise in blood glucose level.(48) This may 354 Journal of the Royal Society of Medicine 114(7)”
BackgroundSodium Glucose Cotransporter Inhibitors for the Treatment of Diabetes
Jesus, A. R., Harrison, B. A., & Dore, T. M. (2021) · Wiley eBooks · doi:10.1002/0471266949.bmc277
Clinical pearls in hospital nephrology
Hamadah, A. M., Fülöp, T., & Gharaibeh, K. A. (2021) · Journal of Community Hospital Internal Medicine Perspectives · doi:10.1080/20009666.2021.1899582
“The mechanism for euglycemia, although possibly complex, may be facilitated by the urinary loss of glucose which lowers serum glucose [17].”
BackgroundMori, V. D. (2020) · The Journal of AMD · doi:10.36171/jamd20.23.2.2
Euglycemic ketoacidosis complicating empagliflozin therapy in a Bangladeshi type 2 diabetic lady
Laboni, R., Afsana, F., Hossain, K. N., Rouf, R. S. B., Amin, M. F., Ashrafuzzaman, S., & Pathan, M. F. (2021) · BIRDEM Medical Journal · doi:10.3329/birdem.v11i3.55229
Gute Diabetestherapie kann auch aus dunklen Tunneln helfen
Hollenrieder, V. (2020) · Info Diabetologie · doi:10.1007/s15034-020-2183-1
Hyperglycemic Crises in Patients with Covid-10
Mikhail, N. E. (2020) · Journal of Clinical Research and Reports · doi:10.31579/2690-1919/114
Metadata
- Authors
- Rosenstock, J., & Ferrannini, E.
- Affiliations
- Medical City Dallas Hospital (US)
- Istituto di Fisiologia Clinica (IT)
- Corresponding author
- Rosenstock, Julio
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2015-08-10
- Volume
- 38
- Issue
- 9
- Pages
- 1638-1642
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W1955935325
- Cited by
- 664
- References
- 21
- Citations by year
- 2026: 23 · 2025: 33 · 2024: 55 · 2023: 36 · 2022: 43 · 2021: 68 · 2020: 89 · 2019: 79 · 2018: 67 · 2017: 75 · 2016: 77 · 2015: 18
- FWCI
- 68.35
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Keywords
- euglycemic diabetic ketoacidosis, SGLT2 inhibitors, drug safety, type 2 diabetes, type 1 diabetes, insulin-treated patients, adverse drug reactions, risk factors, alcohol consumption, intercurrent illness
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.